No negative effects in DMO patients reported following pandemic-imposed health care restrictions

Article

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all terciles.

No negative effects in DMO patients reported following pandemic-imposed health care restrictions

Bryce Johnson, BS, and associates from the Department of Ophthalmology, University of Texas Southwestern Medical Centre, Dallas, found that to their surprise diabetic macular oedema (DMO), a leading cause of vision loss, was not negatively impacted by the changes imposed by the COVID-19 pandemic.

Because a healthy lifestyle is key to prevention of progression of DMO, they conducted a retrospective chart review to assess the impact of truncated medical services during the pandemic.

The study includes 570 patients who had been diagnosed with DMO between January 2019 and July 2021.

The parameters studied were haemoglobin A1c, body mass index, adherence to scheduled appointments, and need for therapy.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all terciles. Most of the macular regions showed some decrease in the macular thickness, the results showed.

Stratification of the patients based on the patient adherence to scheduled appointments did not significantly change the results.

“The DMO did not worsen during the pandemic, and instead we saw a small but significant improvement,” they commented.

They hypothesized that more positive lifestyle changes during the pandemic, delays in retinal changes, and implementation of telehealth evaluation may be possible explanations for the study findings.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.